Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Preliminary studies suggested that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of Cannabis sativa L., might be effective in the treatment of Tourette syndrome (TS). This study was performed to investigate for the first time under controlled conditions, over a longer-term treatment period, whether THC is effective and safe in reducing tics in TS. Method In this randomized, double-blind, placebo-controlled study, 24 patients with TS, according to DSM-III-R criteria, were treated over a 6-week period with up to 10 mg/day of THC. Tics were rated at 6 visits (visit 1, baseline; visits 2-4, during treatment period; visits 5-6, after withdrawal of medication) using the Tourette Syndrome Clinical Global Impressions scale (TS-CGI), the Shapiro Tourette-Syndrome Severity Scale (STSSS), the Yale Global Tic Severity Scale (YGTSS), the self-rated Tourette Syndrome Symptom List (TSSL), and a videotape-based rating scale. Results Seven patients dropped out of the study or had to be excluded, but only 1 due to side effects. Using the TS-CGI, STSSS, YGTSS, and video rating scale, we found a significant difference (p Conclusion Our results provide more evidence that THC is effective and safe in the treatment of tics. It, therefore, can be hypothesized that the central cannabinoid receptor system might play a role in TS pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum
Gerdeman, G., & Lovinger, D. M. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.1.468 · Cited by 433
A Functional Neuroanatomy of Tics in Tourette Syndrome
Stern, E., Silbersweig, D. A., Chee, K.-Y., Holmes, A., Robertson, M. M., Trimble, M., Frith, C. D., Frackowiak, R. S. J., & Dolan, R. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.741 · Cited by 333
Cited by
Items 201–272 of 272
Cannabinoids and the Tourette syndrome
Müller‐Vahl, K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00010-2 · Cited by 3
Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis
Hoch, E., Schneider, M., von Keller, R., Bonnet, U., Falkai, P., Hasan, A., Häuser, W., Hinz, B., Jakob, L., Kabisch, J., et al. (2018) · Springer eBooks · doi:10.1007/978-3-662-57291-7_4 · Cited by 2
(2007) · Humana Press eBooks · doi:10.1007/978-1-59259-887-8_2 · Cited by 2
Neurology — to be or not to be of the cannabis-based medicine?
Szejko, N. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.2022.0021 · Cited by 2
“Almost all researchers conclude their articles on this topic with a statement concerning the urgent need for the preparation of larger, multi-national RCTs that would help us to reach better conclusions regarding CBM safety and efficacy in neurological disorders.”
MethodInfluentialTherapeutic Uses of Medical Cannabis: An Overview of its Functions in Disease Management
Kayode, A. A. A., Adrish, S., Muhammad, A., Amin, R., Muhammad, D., Rida, Z., Alabi, G. O., Okumede, G. F., & Kayode, O. T. (2023) · Journal of Medical Sciences(Faisalabad) · doi:10.3923/jms.2023.32.39 · Cited by 2
Licensed Medical Cannabis Use in Gilles de la Tourette Syndrome: A Retrospective Long-term Follow-Up
Anis, S., Zalomek, C., Korczyn, A. D., Lassman, S., Rosenberg, A., & Gurevich, T. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0281 · Cited by 3
Neurobiological Background of Tic Disorders
Roessner, V., & Rothenberger, A. (2008) · KARGER eBooks · doi:10.1159/000118519 · Cited by 5
Endogenous cannabinoids − a local message in and between the nervous and immune system
Ullrich, O., & Schneider‐Stock, R. (2005) · Signal Transduction · doi:10.1002/sita.200400043 · Cited by 2
Behavioral Effects of Endocannabinoids
Fride, E., Thiébot, M.-H., Onaivi, E. S., & Chaperon, F. (2005) · CRC Press eBooks · doi:10.1201/9781420023640.ch13 · Cited by 2
Tejeda-Martínez, A. R., Paredes, J. M. V., & Flores-Soto, M. E. (2022) · Neurology Perspectives · doi:10.1016/j.neurop.2022.07.003 · Cited by 2
Streetz, C. M., Szejko, N., Pisarenko, A., Fremer, C., Teske, J., Brunnauer, A., & Müller‐Vahl, K. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1595649 · Cited by 1
Kishi, Y., Takumi, I., & Nakajima‐Ohyama, K. C. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70383 · Cited by 2
Medical Marijuana: Facts and Questions
Gupta, S. S., Namana, V., Ambesh, P., Kapoor, S., Abbasi, A. A., & Kamholz, S. L. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000716 · Cited by 1
Tics and Gilles de la Tourette Syndrome
Singer, H. S. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00034-9 · Cited by 2
Vesić, K., Dejanovic, S. D., Borovčanin, M., Samardžić, J., & Tončev, G. (2016) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2015-0047 · Cited by 2
“Small randomized controlled trials have shown a positive effect of cannabis preparations in the treatment of tics in Tourette syndrome (24) and levodopa-induced dyskinesia in Parkinson’s disease (25).”
BackgroundThe Current Understanding of Premonitory Urge Phenomena in Chronic Tic Disorders
Raines, J. M., & Specht, M. W. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0099-9 · Cited by 1
Pharmacological Management of Tic Disorders in Youth
Saggu, B. M., Shad, S., Barnes, A. A., & Budman, C. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811980-8.00004-2 · Cited by 2
Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration
Brašić, J. R., Mari, Z. K., Lerner, A., Raymont, V., Zaidi, E., & Wong, D. F. (2018) · International Journal of Physical Medicine & Rehabilitation · doi:10.4172/2329-9096.1000472 · Cited by 1
“He daily utilizes an inhaled vapor of THC nightly.”
InfluentialKoob, G. F., & Moal, M. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012419239-3/50044-8 · Cited by 1
Treatments with cannabinoids and brain development
Schönhofen, P., de Vargas, D. M., Parsons, R. B., & Klamt, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817988-8.00036-1 · Cited by 1
The pharmacological treatment of Tourette syndrome
Baizabal‐Carvallo, J. F., & Jankovic, J. J. (2022) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.12.007 · Cited by 1
Case Report: Secondary bilateral parkinsonism and dystonia treated with dronabinol
Szejko, N., Burger, F., Sidoroff, V., & Wenning, G. K. (2020) · F1000Research · doi:10.12688/f1000research.26476.2 · Cited by 1
Therapeutic Uses of Medical Cannabis: An Overview of its Functions in Disease Management
Kayode, A. A. A., Adrish, S., Muhammad, A., Amin, R., Muhammad, D., Rida, Z., Alabi, G. O., Okumede, G. F., & Kayode, O. T. (2023) · Journal of Medical Sciences(Faisalabad) · doi:10.3923/jms.2023.24.31 · Cited by 1
Medical use of cannabis: Applications to Tourette syndrome
Szejko, N., & Müller‐Vahl, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00021-1 · Cited by 1
Abdallah, S. B., Fasching, L., Brady, M. V., Bloch, M. H., Lombroso, P. J., Vaccarino, F. M., & Fernandez, T. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00044-3 · Cited by 1
Cannabis Use in Epilepsy—Risks and Benefits
Holtkamp, M., & Hamerle, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00050-8 · Cited by 1
Yale Global Tic Severity Scale (YGTSS)
Murphy, T. K., Storch, E. A., & Bodzin, D. K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374105-9.00391-9 · Cited by 1
Preparation of neoclerodane diterpenes as probes for the opioid receptor system
Lozama, A., Prisinzano, T. E., Wiemer, D. F., Doorn, J. A., Olivo, H. F., Salem, A. K., & Duffel, M. W. (2010) · doi:10.17077/etd.57godcye · Cited by 1
Lin, L., Lan, Y., Yu, L., Wang, S., Wu, S., Wan, W., Hou, T., Zhang, H., Ge, W., Chen, C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2265002/v1 · Cited by 1
Roessner, V., Mehler‐Wex, C., & Warnke, A. (2009) · Springer eBooks · doi:10.1007/978-3-211-79275-9_28
Untersuchungen zur Monozyten-Stimulierbarkeit bei Tourette-Syndrom
Wildenauer, A. (2011) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.13711
Ticstörungen und Tourette-Syndrom
Neuner, I., & Schneider, F. W. (2015) · Springer eBooks · doi:10.1007/978-3-642-54571-9_25
Los cannabinoides en la práctica clínica: Un debate abierto
Durán, M. (2004) · Monografías humanitas
Cannabinoid-Based Medicines for the Treatment of Gilles de la Tourette Syndrome
Kanaan, A. S., & Müller‐Vahl, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00107-1 · Cited by 3
Singer, H. S., Mink, J. W., Gilbert, D. L., & Jankovic, J. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7506-9852-8.00006-0
The endocannabinoid system and trichotillomania
Grant, J. E., Odlaug, B. L., & Chamberlain, S. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00017-5 · Cited by 1
TRATAMIENTO FARMACOLÓGICO DEL TDAH Y LAS COMORBILIDADES
Prince, J. B., & Wilens, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-84-458-2021-6.00019-1
Drug and Non-drug Treatment of Tourette Syndrome
Zelnik, N. (2019) · Current Drug Therapy · doi:10.2174/1574885514666191121141923
Behandlung des Tourette-Syndroms mit cannabisbasierten Medikamenten
Müller‐Vahl, K. (2020) · Nervenheilkunde · doi:10.1055/a-1096-4937
“In einer Folgestudie wurden 24 erwachsene Patienten mit GTS über einen Zeitraum von 6 Wochen mit bis zu 10 mg THC pro Tag behandelt [21].”
BackgroundCannabinoids in Neurologic Conditions
Gaston, T. E., Szaflarski, J. P., Bowling, A. C., Liu, Y., Seawalt, T., Leehey, M. A., Nelson, E. L., Rajpal, S., Villavicencio, A. T., Bauer, A. M., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-45968-0_10
Cannabisarznei zur Behandlung psychischer Störungen
Hoch, E., Preuss, U. W., & Pogarell, O. M. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1271-z
Montalbano, G. E., Yang, J. W., Nurmi, E. L., & Ricketts, E. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00042-x
Bortolato, M., & Cadeddu, R. (2022) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.12.008
Fasching, L., Brady, M. V., Bloch, M. H., Lombroso, P. J., & Vaccarino, F. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00040-0
Ticstörungen und Tourette-Syndrom
Ludolph, A. G. (2011) · Springer eBooks · doi:10.1007/978-3-642-19846-5_29
Yale Global Tic Severity Scale (YGTSS)☆
Murphy, T. K., Storch, E. A., Wolfe, A. M., & Bodzin, D. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.00863-4
Complementary and Integrative Health Medicine in Tourette Syndrome
Cruz, M., & Coffey, B. J. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197543214.003.0029
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_465
El uso terapéutico del cannabis y los cannabinoides
Silva, J. P., & Carvalho, F. D. (2022) · Revista Española de Drogodependencias · doi:10.54108/10031 · Cited by 1
Smoke gets in your ticsPreprint
BLACK, K. J. (2023) · Authorea · doi:10.22541/au.149308896.61629534/v3
Roessner, V., & Rothenberger, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_26
Mann, G. S., Gadelmawla, A. F., Dway, A., Fayaz, F. H., Kebede, E., Varadharaj, N. K., Akram, A., Khan, A., Azuwike, U. B., Sampangi, B. K., et al. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.044
Psychopharmacology for Pediatric Tics and Tourette’s Disorder
Coffey, B. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_9
OS BENEFÍCIOS DO CANABIDIOL NO TRATAMENTO EM CRIANÇAS COM TRANSTORNOS NEURODIVERGENTES
Albuquerque, S. C. B., & de Mendonça, L. A. (2024) · Revista Contemporânea · doi:10.56083/rcv4n10-222
Gilles De La Tourette Syndrome
Gravino, G. (2013) · Annals of Clinical Psychiatry · doi:10.1177/104012371302500410 · Cited by 2
“…and ropinirole), which clinicians should avoid because of side effects from ergot content, 108,109 delta-9-tetrahydrocannabinol, which has been effective but is illegal in most countries, 110,111 and Botulinum toxin (Botox), which has been used to treat both motor and vocal tics successfully.”
Hardeman, L. S., Farhat, L. C., Koenig, J., & Bloch, M. H. (2025) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.70075
Figueiredo, J. F. L. M., Silva, J. V. S., Soares, C. D. A., de Oliveira, L. T. J., Sacramento, V. D. M., de Oliveira, D. A., & Royo, V. D. A. (2025) · Brazilian Journal of Medical and Health Sciences · doi:10.64597/72v2pe54
Boury‐Esnault, N., Marschal, C., Probst, J.-M. K., & Barnathan, G. (2002) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.155630
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517185
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517173
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517164
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517176
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517179
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517167
Investigating medical cannabis for adolescents with Tourette syndrome: tread carefully
Abi‐Jaoude, E. (2026) · BJPsych Open · doi:10.1192/bjo.2025.10959
Koob, G. F., Arends, M. A., McCracken, M. L., & Moal, M. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-12-816791-5.00001-7
van de Griendt, J. M. T. M. (2026) · Radboud Repository (Radboud University)
Bharat, C., Huang, X., Campbell, G., Tisdale, C., Glasgow, S., Nielsen, S., Pollock, Z., Santo, T., Kale, S., Farrell, M., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117380
Cannabinoids and therapeutic potential in neuropsychiatry
Ertenu, D. D., Papolu, A., Anderson, N., Wecker, E., Hauptman, A. J., & Salpekar, J. A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.030
Targeting Dopamine Pathways for the Treatment of Tourette Syndrome
Karkanias, G. B., Flatt, J. A., Korb, R. T., Munschauer, F. E., Wanaski, S. P., Cunniff, T. M., & Gilbert, D. L. (2026) · Journal of Child Neurology · doi:10.1177/08830738261491159
Metadata
- Authors
- Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Heinrich Heine University Düsseldorf (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-04-15
- Volume
- 64
- Issue
- 4
- Pages
- 459-465
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1981252279
- Cited by
- 270
- References
- 29
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 13 · 2023: 17 · 2022: 27 · 2021: 15 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 6 · 2013: 5 · 2012: 10
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- delta-9-tetrahydrocannabinol, Tourette syndrome, tics, cannabis, tic reduction, drug safety, Tourette syndrome treatment
- MeSH terms
- Adolescent, Adult, Double-Blind Method, Drug Administration Schedule, Female, Tourette Syndrome, Humans, Male, Middle Aged, Personality Inventory, Placebos, Psychiatric Status Rating Scales, Receptors, Drug, Severity of Illness Index, Dronabinol, Treatment Outcome, Tics, Receptors, Cannabinoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.